new_0222_0346|TPTX|0|total_current_assets|cash_on_hand|inventories_net|net_ppe|goodwill_and_intangible|liabilities|total_current_liabilities|total_long_term_liab|total_deposits|book_value_of_equity|retained_earnings|treasury_stock|ev_revenues|ev_earnings|ev_free_cash_flow|ev_assets|ps_ratio|pe_ratio|price_to_book_value|peg_ratio|debt_equity_ratio|dividend_yield|shareholder_yield_ttm|percent_of_shares_outstanding|receivables|payables|capital_stock|return_on_invested_capital|quality_ratio_fractile|momentum_fractile|market_beta_12_month|sustainable_growth_rate|institutional_investor_ownership_percentage|average_shares_outs_diluted|total_employee_number|eps|sga_expense|shares_outstanding|repurchase_of_capital_stock|ordinary_shares_number|payout_ratio|quick_ratio|normalized_eps|stock_buyback|effective_tax_rate|return_on_equity|net_income_ttm|revenues_ttm|dividend_per_share|revenues|gross_profit|pre_tax_income|net_income|interest_income|price|total_return_price|enterprise_value|average_volume_30|one_year_return|short_interest|forward_pe_ratio|forward_pe_ratio_1y|forward_ps_ratio|forward_ps_ratio_1y|quarterly_eps_estimates|quarterly_sales_estimates|quarterly_eps_surprise|quarterly_sales_surprise|quarterly_eps_actual|quarterly_sales_actual|sales_est_0y|sales_est_1y|price_target|consensus_recommendation|price_target_num_est|eps_est_0y|eps_est_1y|r_and_d_expense|reconciled_depreciation|interest_expense_non_operating|land_and_improvements|buildings_and_improvements|other_properties|machinery_furniture_equipment|price_next_month|price_second_month new_0222_0346|TPTX|1|Turning Point Therapeutics Inc Total Current Assets (Quarterly) (USD)|Turning Point Therapeutics Inc Cash and Short Term Investments (Quarterly) (USD)|Turning Point Therapeutics Inc Inventories (Quarterly) (USD)|Turning Point Therapeutics Inc Net PP&E (Quarterly) (USD)|Turning Point Therapeutics Inc Goodwill and Intangibles (Quarterly) (USD)|Turning Point Therapeutics Inc Total Liabilities (Quarterly) (USD)|Turning Point Therapeutics Inc Total Current Liabilities (Quarterly) (USD)|Turning Point Therapeutics Inc Total Long Term Liabilities (Quarterly) (USD)|Turning Point Therapeutics Inc Total Deposits (Quarterly) (USD)|Turning Point Therapeutics Inc Book Value (Quarterly) (USD)|Turning Point Therapeutics Inc Retained Earnings (Quarterly) (USD)|Turning Point Therapeutics Inc Treasury Stock (Quarterly) (USD)|Turning Point Therapeutics Inc EV to Revenues|Turning Point Therapeutics Inc EV to Earnings|Turning Point Therapeutics Inc EV to Free Cash Flow|Turning Point Therapeutics Inc EV to Assets (Quarterly)|Turning Point Therapeutics Inc PS Ratio|Turning Point Therapeutics Inc PE Ratio|Turning Point Therapeutics Inc Price to Book Value|Turning Point Therapeutics Inc PEG Ratio|Turning Point Therapeutics Inc Debt to Equity Ratio|Turning Point Therapeutics Inc Dividend Yield|Turning Point Therapeutics Inc Shareholder Yield (TTM)|Turning Point Therapeutics Inc Percent of Shares Outstanding Short|Turning Point Therapeutics Inc Total Receivables (Quarterly) (USD)|Turning Point Therapeutics Inc Total Payables (Quarterly) (USD)|Turning Point Therapeutics Inc Total Capital Stock (Quarterly) (USD)|Turning Point Therapeutics Inc Return on Invested Capital|Turning Point Therapeutics Inc Quality Ratio Score|Turning Point Therapeutics Inc Momentum Score|Turning Point Therapeutics Inc Beta (1Y)|Turning Point Therapeutics Inc Sustainable Growth Rate (TTM)|Turning Point Therapeutics Inc Institutional Investor Ownership Percentage|Turning Point Therapeutics Inc Average Diluted Shares Outstanding (Quarterly)|Turning Point Therapeutics Inc Total Employees (Annual)|Turning Point Therapeutics Inc EPS Diluted (Quarterly) (USD)|Turning Point Therapeutics Inc SG&A Expense (Quarterly) (USD)|Turning Point Therapeutics Inc Shares Outstanding|Turning Point Therapeutics Inc Repurchase of Capital Stock (Quarterly) (USD)|Turning Point Therapeutics Inc Ordinary Shares Number (Quarterly)|Turning Point Therapeutics Inc Payout Ratio|Turning Point Therapeutics Inc Quick Ratio (Quarterly)|Turning Point Therapeutics Inc Normalized Diluted EPS (Quarterly) (USD)|Turning Point Therapeutics Inc Stock Buybacks (Quarterly) (USD)|Turning Point Therapeutics Inc Effective Tax Rate (TTM)|Turning Point Therapeutics Inc Return on Equity|Turning Point Therapeutics Inc Net Income (TTM) (USD)|Turning Point Therapeutics Inc Revenue (TTM) (USD)|Turning Point Therapeutics Inc Dividend Per Share (Quarterly) (USD)|Turning Point Therapeutics Inc Revenue (Quarterly) (USD)|Turning Point Therapeutics Inc Gross Profit (Quarterly) (USD)|Turning Point Therapeutics Inc Pre-Tax Income (Quarterly) (USD)|Turning Point Therapeutics Inc Net Income (Quarterly) (USD)|Turning Point Therapeutics Inc Net Interest Income (Quarterly) (USD)|Turning Point Therapeutics Inc Price (USD)|Turning Point Therapeutics Inc Total Return Price (USD)|Turning Point Therapeutics Inc Enterprise Value (USD)|Turning Point Therapeutics Inc 30-Day Average Daily Volume|Turning Point Therapeutics Inc 1 Year Price Returns (Daily)|Turning Point Therapeutics Inc Short Interest|Turning Point Therapeutics Inc PE Ratio (Forward)|Turning Point Therapeutics Inc PE Ratio (Forward 1y)|Turning Point Therapeutics Inc PS Ratio (Forward)|Turning Point Therapeutics Inc PS Ratio (Forward 1y)|Turning Point Therapeutics Inc Quarterly EPS Estimates (USD)|Turning Point Therapeutics Inc Quarterly Revenue Estimates (USD)|Turning Point Therapeutics Inc Quarterly EPS Surprise|Turning Point Therapeutics Inc Quarterly Revenue Surprise|Turning Point Therapeutics Inc Quarterly Actual EPS (USD)|Turning Point Therapeutics Inc Quarterly Actual Revenue (USD)|Turning Point Therapeutics Inc Revenue Estimates for Current Fiscal Year (USD)|Turning Point Therapeutics Inc Revenue Estimates for Next Fiscal Year (USD)|Turning Point Therapeutics Inc Price Target (USD)|Turning Point Therapeutics Inc Consensus Recommendation|Turning Point Therapeutics Inc Price Target Num Estimates|Turning Point Therapeutics Inc EPS Estimates for Current Fiscal Year (USD)|Turning Point Therapeutics Inc EPS Estimates for Next Fiscal Year (USD)|Turning Point Therapeutics Inc Research and Development Expense (Quarterly) (USD)|Turning Point Therapeutics Inc Reconciled Depreciation (Quarterly) (USD)|Turning Point Therapeutics Inc Non-Operating Interest Expense (Quarterly) (USD)|Turning Point Therapeutics Inc Land and Improvements (Quarterly) (USD)|Turning Point Therapeutics Inc Buildings and Improvements (Quarterly) (USD)|Turning Point Therapeutics Inc Other Properties (Quarterly) (USD)|Turning Point Therapeutics Inc Machine, Furniture & Equipment (Quarterly) (USD)|| new_0222_0346|TPTX|2|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|percent_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_beta|percent_USD_metric|percent_USD_metric|mil_figure_USD_metric|figure_whole_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_money_USD_price|mil_figure_money_USD_metric|figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_per_share_metric|percent_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_USD_metric|figure_whole_USD_price|figure_money_USD_per_share_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|| new_0222_0346|TPTX|4|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|quarterly|quarterly|daily|quarterly|quarterly|daily|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|daily|monthly|quarterly|quarterly|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|monthly|daily|monthly|monthly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|| new_0222_0346|TPTX|5|91.2727272727|91.2727272727||91.2727272727||91.2727272727|91.2727272727|91.2727272727||91.2727272727|91.2727272727|||92|6.92|91.25|||6.92805755396||91.25|1.44769874477|92|15.2575757576||91.2727272727|91.2727272727|92||32.1052631579|30.5238095238|92||91.3571428571|92.7|91.3571428571|91.3571428571|31.1666666667||91.2727272727|92|91.25|91.3571428571|91.3846153846||92|91.2727272727|||91.25||91.3571428571|91.3571428571|91.5|6.96644295302|6.96644295302|6.96644295302|6.95804195804|1.44516129032|15.2575757576|||1.44712430427|1.44712430427|91.3333333333|91.3333333333|91.2857142857|91|91.2857142857|91.2857142857|19.0943396226|28.6285714286|12.65|6.65789473684|12.65|14.2535211268|16.4|91.3571428571|91.3571428571|||91.2727272727|91.2727272727|91.2727272727|| new_0222_0346|TPTX|6|11|11||11||11|11|11||11|11|||1|150|4|||139||4|717|1|66||11|11|1||19|21|1||14|10|14|14|30||11|1|4|14|13||1|11|||4||14|14|2|149|149|149|143|465|66|||539|539|12|12|7|2|7|7|53|35|80|152|80|71|60|14|14|||11|11|11|| new_0222_0346|TPTX|7|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|daily|quarterly|daily|daily|daily|daily|quarterly|daily|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|monthly|quarterly|yearly|quarterly|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|market_daily|market_daily|daily|market_daily|market_daily|daily|daily|daily|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|daily|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|| new_0222_0346|TPTX|201803||||||||||||||||||||||||||||||||||14.938||-0.3168|0.516||||||-0.3168|||||||||-4.733|-4.733|0.127||||||||||||||||||||||||4.344|0.018||||||| new_0222_0346|TPTX|201806||||||||||||||||||||||||||||||||||14.938||-0.3372|0.803||||||-0.3372|||||||||-5.037|-5.037|0.135||||||||||||||||||||||||4.369|0.021||||||| new_0222_0346|TPTX|201809||||||||||||||||||||||||||||||||||14.938||-0.4015|1||||||-0.4015|||||||||-5.997|-5.997|0.132||||||||||||||||||||||||5.129|0.025||||||| new_0222_0346|TPTX|201812|101.523|101.029||1||151.686|5.322|146.364||-48.406|-50.753|||||||||||||||1.494|0.001|||||||14.938||-0.6037|2.259|||27.7577|||-0.6037||||-24.785|||||-9.018|-9.018|||||||||||||||||||||||||7.221|0.074||||0.388|0.204|| new_0222_0346|TPTX|201903|91.359|90.011||2.487||155.503|8.122|147.381||-60.005|-64.3||||-26.1772|||||||||0.1116||2.697|0.001|||||||27.7577|63|-0.488|3.614|29.6547||27.7577|||-0.488|-0.022|||-33.599|||||-13.547|-13.547||29.37|29.37|747.4377|302792.1333||33096|||||||||||||48.25|1.25|4|-3.88|-2.815|10.451|0.239|||1.529|0.4|0.225|38.8| new_0222_0346|TPTX|201906|255.168|250.17||2.204||9.53|7.888|1.642||247.915|-81.442||||-39.5506||||5.032|||||3.7661||4.086|0.034|||||||24.4798|77|-0.7|4.743|31.2974||31.2974|||-0.7|-175.129|||-45.704|||||-17.142|-17.142||38.92|38.92|1129.2889|194807.1333||1175022|||||||||||||49.5|1.25|4|-3.88|-2.815|13.711|0.322|||1.25|0.508|0.101|39.49|54.53 new_0222_0346|TPTX|201909|429.37|423.575||6.945||15.864|11.72|4.144||420.524|-101.925||||-28.9722||||5.8124|||||6.3532||3.811|0.004|||||||32.3128|87|-0.63|5.5|35.8392||35.8392|||-0.63|-190.186|||-60.19|||||-20.483|-20.483||36.9|36.9|1172.5351|309190.4667||2276949|||||||||||||59|1.2857|6|-3.37|-2.7875|16.64|0.468|||4.761|0.785|0.909|36.64|56.22 new_0222_0346|TPTX|201912|414.947|409.151||7.182||17.851|14.032|3.819||404.351|-122.884||||-34.1374||||5.5327|||||6.2878||2.15|0.004|||||||35.9628|95|-0.58|5.924|35.9151||35.9151|||-0.58|0.681|||-72.131|||||-20.959|-20.959||60.63|60.63|1795.8675|633740.5||2258262|||89.4861|72.5603|-0.6067||4.3961||-0.58||||65|1.375|8|-3.4317|-4.112|17.141|0.55|||4.493|0.885|1.267|58.5|49.57 new_0222_0346|TPTX|202003|389.396|380.782||6.88||14.642|11.155|3.487||381.707|-183.602||||-21.1719||||4.2029|||||8.4364||1.846|0.004|||10|1.2415|||35.9194|102|-1.69|39.857|35.9222||35.9222|||-1.69||||-119.302|||||-60.718|-60.718||42.1|42.1|1259.748|363767.8|48.0172|3030533|||64.1714|52.0338|-0.6467||-26.2004||-0.8161||||65.25|1.375|8|-2.88|-3.5367|22.769|0.588|||4.219|1.064|1.267|53.37|63.81 new_0222_0346|TPTX|202006|718.876|710.43||6.475||14.597|11.449|3.148||710.827|-215.095||||-31.5217||||3.8317|||||6.7794||1.33|0.005|||10|1.419|||38.6032|109|-0.82|8.578|42.1689||42.1689|||-0.82|-351.611|||-133.653|||||-31.493|-31.493||64.59|64.59|2446.0854|509579.6667|58.6978|2858794|||108.9476|88.3408|-0.76||-7.8947||-0.82||8.3333|0.5556|79.5|1.375|8|-3.4733|-3.75|24.154|0.594|||3.938|1.121|1.301|60.43|79.43 new_0222_0346|TPTX|202009|718.163|711.388||6.202||23.045|20.256|2.789||701.588|-232.8||||-33.4509|4.1074|||5.2531|||||8.9014||4.552|0.005|||8|1.5427|||42.1858|130|-0.42|11.326|42.2134||42.2134||35.1199|-0.42||||-130.875|||25||-17.705|-17.705||88.55|88.55|2811.5165|391565.8333|132.3404|3757600|||147.5105|119.6098|-0.675|12.5|37.7778|100|-0.42|25|11.1111||85.4444|1.3333|9|-2.965|-3.7117|32.213|0.604|||3.651|1.347|1.313|100.08|104.58 new_0222_0346|TPTX|202012|1130.679|1122.508||5.961||26.815|24.392|2.423||1109.898|-280.176||||-82.7451|4.2306|||8.6864|||||4.5139||5.225|0.005|||9|1.3062|||46.6308|142|-1.02|13.664|48.6785||48.6785||46.0195|-1.02|-433.858|||-157.292|||||-47.376|-47.376||120.31|120.31|5382.9023|324529.8667|95.6173|2197320|||192.383|1115.5471|-0.8667||-17.6919||-1.02||25|0.5|129.1|1.4|10|-3.3975|-4.062|34.275|0.607|||3.357|1.629|1.313|128.07|117.28 new_0222_0346|TPTX|202103|1121.912|1114.777||5.565||26.419|24.371|2.048||1101.165|-315.68||||-38.9049|3.1317|||3.9578|||||4.8679||6.784|0.005|||8|0.8511|||48.9204|169|-0.73|19.991|49.117||49.117||45.7419|-0.73||||-132.078|||25.205||-35.504|-35.504||89.5|89.5|3270.2326|355928.6|111.8003|2390982|||150.6888|873.7803|-0.648|17.5|-12.6543|44.0286|-0.73|25.205|18|50.1699|160|1.4|10|-3.836|-5.6|41.263|0.633|||3.056|1.678|1.422|78.26|68.86 new_0222_0346|TPTX|202106|1091.42|1077.806||9.479||35.413|31.895|3.518||1067.507|-371.953|||-17.6958|-36.5359|2.5167|||3.3867||||-11.2587|6.4757||7.088|0.005|-15.764||2|0.3713|-16.7191||49.2044||-1.14|17.171|49.3917||49.3917||33.7923|-1.14|||-16.7191|-156.858|||5.164||-56.273|-56.273||75.87|75.87|2614.5825|575869.8667|20.7927|3198475|||124.9867|724.7448|-1.1629||1.9658||-1.14|5.164|25.7589|7.1301|152.5|1.4|10|-4.2|-6.2233|44.65|0.85|||6.269|2.24|1.632|61|77.02 new_0222_0346|TPTX|202109|1047.141|1036.014||9.823||41.648|38.753|2.895||1017.337|-438.278|||-10.9496|-26.1208|2.1246|||3.2394||||-13.2036|4.5797||3.188|0.005|-20.5581||4|0.8284|-20.5581||49.4265|237|-1.34|18.224|49.4642||49.4642||26.7338|-1.34|||-20.5581|-205.478|||0.46||-66.325|-66.325||69.99|69.99|2380.2599|282599.4667|-23.9583|2265306|||106.5759|617.9885|-1.2175||-10.0616||-1.34|0.46|30.3877|5.7871|146.1818|1.5454|11|-4.2562|-5.965|48.889|1.21|||5.965|3.11|1.633|41.64|38.06 new_0222_0346|TPTX|202112|||||||||||||||-10.0965||||2.3642|||||4.4674||||||1|-0.7678||||||||||||||||||||||||48.61|48.61|1369.1845|537903.5|-60.8535|2210462|||488.2714|34.1534|-1.3467|0.1|||||30.9546|4.8337|130|1.5833|10|-4.4678|-6.14||||||||38.08|32.36 new_0222_0346|TPTX|202203|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-1.305||||||||||||||||||||| new_0222_0346|TPTX|202206|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-1.4367|3.125|||||||||||||||||||| new_0222_0346|TPTX|202209|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-1.49|0.7043|||||||||||||||||||| new_0222_0346|TPTX|202212|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-1.5217|||||||||||||||||||||